Crossref
Does Intermediate Molecular Risk Really Justify Total Thyroidectomy?
Clinical Thyroidology® · 01.11.2026 · 38 (11) · 398-401
DOI: 10.1177/23299711261506100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Thyroidology®, online erschienen am 16.11.2026. Verfasst von Fernanda Vaisman. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Vaisman, F. (2026). Does Intermediate Molecular Risk Really Justify Total Thyroidectomy?. Clinical Thyroidology®, 38(11), 398-401. https://doi.org/10.1177/23299711261506100
Vancouver
Vaisman F. Does Intermediate Molecular Risk Really Justify Total Thyroidectomy?. Clinical Thyroidology®. 2026;38(11):398-401. doi:10.1177/23299711261506100
BibTeX
@article{Vaisman2026,
author = {Vaisman, Fernanda},
title = {Does Intermediate Molecular Risk Really Justify Total Thyroidectomy?},
journal = {Clinical Thyroidology®},
year = {2026},
volume = {38},
number = {11},
pages = {398--401},
doi = {10.1177/23299711261506100}
}
EUVIMED